Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,200.00 Price Target at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by Wells Fargo & Company from $1,125.00 to $1,200.00 in a research report report published on Friday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a research report on Tuesday, July 23rd. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research report on Thursday, July 11th. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an overweight rating in a research report on Monday, June 17th. Truist Financial restated a buy rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday. Finally, Argus upped their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $10.95 on Friday, reaching $1,082.19. 646,247 shares of the company’s stock traded hands, compared to its average volume of 415,793. The firm has a market cap of $119.25 billion, a price-to-earnings ratio of 31.97, a P/E/G ratio of 2.34 and a beta of 0.13. The stock has a 50 day moving average price of $1,043.43 and a 200-day moving average price of $982.47. Regeneron Pharmaceuticals has a fifty-two week low of $759.15 and a fifty-two week high of $1,115.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Equities research analysts predict that Regeneron Pharmaceuticals will post 37.38 EPS for the current fiscal year.

Insider Activity

In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 1,172 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 65,074 shares of company stock valued at $64,546,123 in the last 90 days. Company insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. West Paces Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.